托弗森治疗SOD1型肌萎缩侧索硬化症的长期疗效
本文整合VALOR随机双盲安慰剂对照试验及其开放标签扩展研究,评估托弗森治疗SOD1-ALS成人患者的长期效果。共108例携带42种SOD1致病变异的患者入组,早期用药组在148周内临床功能、呼吸功能、肌力和生活质量的下降幅度数值上均小于延迟用药组,并较自然病史预期延长生存,多数不良事件与疾病进展或已知操作相关。
要点
- 早期启动托弗森在148周内各项功能指标下降数值上小于延迟启动组。
- 托弗森相对SOD1-ALS自然病史预期延长了生存。
- 严重神经系统不良事件均可逆,仅少数导致停药。
核心结论
- VALOR与开放标签扩展研究的最终数据支持托弗森在SOD1-ALS中的获益,并为其在该人群中的使用提供明确依据。
研究设计与样本
- 3期随机双盲安慰剂对照VALOR试验于2019年3月至2021年7月在10国32个中心开展,108例携带SOD1致病变异的成人按2:1随机接受托弗森100 mg或安慰剂24周。
- 108例中95例(88%)进入开放标签扩展研究,46例完成,至扩展研究完成时随访可达192-276周。
主要发现
- 148周内早期启动组较延迟启动组ALSFRS-R评分下降-9.9分对-13.5分,慢肺活量下降-13.8%对-18.1%。
- 握力计肌力综合评分下降-0.38分对-0.43分,ALSAQ-5评分17.0分对22.5分,EQ-5D-5L评分-0.1对-0.2。
- 托弗森相对SOD1-ALS自然病史预期延长了生存。
- 多数不良事件与ALS进展或已知操作相关,严重神经系统不良事件均可逆。
关键数值与推荐
- VALOR中托弗森剂量为100 mg,随机分配比例2:1,治疗期24周。
- 早期启动组平均(SD)年龄48.1(12.6)岁(n=72),男性43例(60%)。
- 安慰剂/延迟启动组平均(SD)年龄51.2(11.6)岁(n=36),男性19例(53%)。
临床怎么用
- 对确认携带SOD1致病变异的ALS成人,可考虑尽早启动托弗森以减缓功能、呼吸、肌力与生活质量下降。
- 用药期间需监测神经系统不良事件,多数严重事件可逆。
局限性
- 早期与延迟启动的比较为整合分析,部分功能指标差异为数值性而非统计学结论。
- 开放标签扩展研究完成率较低(46/108),长期随访数据存在脱落。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Approximately 2% of amyotrophic lateral sclerosis (ALS) cases are attributable to a pathogenic variant in the superoxide dismutase 1 (SOD1) gene. Tofersen, an intrathecal antisense oligonucleotide designed to reduce SOD1 protein synthesis, is the first and only approved therapy for the treatment of ALS in adults who have a variant in the SOD1 gene. OBJECTIVE: To evaluate the long-term effects of tofersen in adults with SOD1-ALS. DESIGN, SETTING, AND PARTICIPANTS: The phase 3, randomized, double-blind, placebo-controlled VALOR trial (A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tofersen in SOD1-ALS; conducted from March 2019 to July 2021) evaluated tofersen use over 28 weeks in adults (18 years and older) with weaknesses attributable to ALS and a confirmed SOD1 pathogenic variant at 32 sites in 10 countries; participants could then enroll in an open-label extension (OLE; completed August 2024). INTERVENTION AND EXPOSURE: Adults with SOD1-ALS were randomly assigned 2:1 to receive tofersen (100 mg) or placebo over a 24-week period in the VALOR study. All participants in the OLE were treated with tofersen. MAIN OUTCOMES AND MEASURES: Integrated analysis of VALOR and the OLE study aimed to compare early start vs placebo/delayed start (approximately 6 months later) treatment with tofersen. Key efficacy end points included measures of axonal injury and neurodegeneration (neurofilament), function and strength, quality of life, and survival. RESULTS: VALOR enrolled 108 participants with 42 unique SOD1 pathogenic variants (mean [SD] age: placebo/delayed-start group 51.2 [11.6] [n = 36]; early-start group: 48.1 [12.6] [n = 72]) with 19 (53%) and 43 (60%) of participants being male in the placebo/delayed- and early-start groups, respectively. Overall, 95/108 participants (88%) enrolled in the OLE, and 46 participants completed the OLE (early-start group, 34 [47%]; placebo/delayed-start group, 12 [33%]). At OLE completion, participants could have accumulated 3.5 years or more (range, 192-276 weeks) of follow-up from the start of VALOR. Over 148 weeks, earlier initiation of tofersen (compared to later initiation) was associated with numerically less decline in measures of clinical function (Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised score, -9.9 vs -13.5 points), respiratory function (slow vital capacity, -13.8% vs -18.1%), muscle strength (handheld dynamometry megascore, -0.38 vs -0.43 points), and quality of life (Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 score, 17.0 vs 22.5 points; EuroQol 5 Dimension, 5 Level Questionnaire score, -0.1 vs -0.2 points). Tofersen prolonged survival relative to the expected natural history of SOD1-ALS. Most adverse events were consistent with ALS progression or known procedural adverse effects. All serious neurological adverse events were reversible; few led to tofersen discontinuation. CONCLUSIONS AND RELEVANCE: Final data from VALOR and the OLE demonstrated the benefit of tofersen in SOD1-ALS and provide clear rationale for its use in this population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: VALOR NCT02623699; OLE NCT03070119.
引用
- Miller TM, Cudkowicz ME, Shaw PJ, et al. Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis. JAMA Neurol. 2026. PMID: 41661214. doi:10.1001/jamaneurol.2025.4946
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。